MedTrace Logo

Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis

NCT06764862 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2026-04-13

No results posted yet for this study

Summary

This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Conditions

Interventions

DRUG

HSK44459 dose 1

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

DRUG

HSK44459 dose 2

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

DRUG

HSK44459 dose 3

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

DRUG

Placebo

Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-17
Primary Completion
2026-02-12
Completion
2026-03-04

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06764862 on ClinicalTrials.gov